Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease

Koichiro Honma, K. Hayashi, Takeshi Kanda, K. Yoshioka, I. Takamatsu, S. Tatematsu, H. Kumagai, Shu Wakino, T. Saruta

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although multiple antihypertensive agents are required to control blood pressure (BP) in chronic renal disease, it remains undetermined whether the combination therapy with angiotensin receptor blockers (ARB) plus calcium antagonists or angiotensin-converting enzyme inhibitors (ACEI) confers more preferable action on renal disease than the ARB monotherapy. In the present study, we compared the effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug treatment, the candesartan monotherapy (n=19) reduced BP from 154±3/93±2 to 146±3/88±2 mmHg (P< 0.05), and a similar magnitude of BP reductions was observed with the combination therapy with candesartan plus ACEI/amlodipine (from 153±2/95±2 to 144±2/88±2 mmHg, P<0.05, n=39). The depressor action of these therapies was sustained throughout the 12-month treatment. In contrast, the reduction in proteinuria was greater with the combination therapy (-52±3% at 12 months, n=39) than with the candesartan monotherapy (-25±3%, n=19), although the baseline values of proteinuria were nearly the same in the candesartan monotherapy group (1.74±0.22 g/day) and the combination therapy group (2.10±0.19 g/day, P>0.2). Of note, the proteinuria-sparing effect did not differ between the candesartan + ACEI group and the candesartan + amlodipine group. In conclusion, the present study suggests more beneficial action of the combination therapy with ARB plus ACEI/amlodipine than the ARB monotherapy in nondiabetic renal disease. Since the reduction in BP was achieved to the same level, the distinct proteinuria-sparing action of these therapies is attributed to BP-independent mechanisms, which should vary depending on the agents used.

Original languageEnglish
Pages (from-to)879-884
Number of pages6
JournalJournal of Human Hypertension
Volume18
Issue number12
DOIs
Publication statusPublished - 2004 Dec

Fingerprint

Amlodipine
Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Proteinuria
Blood Pressure
Calcium
Kidney
Therapeutics
Antihypertensive Agents
candesartan cilexetil
Pharmaceutical Preparations
candesartan

Keywords

  • ACE inhibitors
  • Amlodipine
  • Candesartan
  • Proteinuria
  • Renal disease

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease. / Honma, Koichiro; Hayashi, K.; Kanda, Takeshi; Yoshioka, K.; Takamatsu, I.; Tatematsu, S.; Kumagai, H.; Wakino, Shu; Saruta, T.

In: Journal of Human Hypertension, Vol. 18, No. 12, 12.2004, p. 879-884.

Research output: Contribution to journalArticle

Honma, Koichiro ; Hayashi, K. ; Kanda, Takeshi ; Yoshioka, K. ; Takamatsu, I. ; Tatematsu, S. ; Kumagai, H. ; Wakino, Shu ; Saruta, T. / Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease. In: Journal of Human Hypertension. 2004 ; Vol. 18, No. 12. pp. 879-884.
@article{af528fa118c24329b87c893f9d41e080,
title = "Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease",
abstract = "Although multiple antihypertensive agents are required to control blood pressure (BP) in chronic renal disease, it remains undetermined whether the combination therapy with angiotensin receptor blockers (ARB) plus calcium antagonists or angiotensin-converting enzyme inhibitors (ACEI) confers more preferable action on renal disease than the ARB monotherapy. In the present study, we compared the effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug treatment, the candesartan monotherapy (n=19) reduced BP from 154±3/93±2 to 146±3/88±2 mmHg (P< 0.05), and a similar magnitude of BP reductions was observed with the combination therapy with candesartan plus ACEI/amlodipine (from 153±2/95±2 to 144±2/88±2 mmHg, P<0.05, n=39). The depressor action of these therapies was sustained throughout the 12-month treatment. In contrast, the reduction in proteinuria was greater with the combination therapy (-52±3{\%} at 12 months, n=39) than with the candesartan monotherapy (-25±3{\%}, n=19), although the baseline values of proteinuria were nearly the same in the candesartan monotherapy group (1.74±0.22 g/day) and the combination therapy group (2.10±0.19 g/day, P>0.2). Of note, the proteinuria-sparing effect did not differ between the candesartan + ACEI group and the candesartan + amlodipine group. In conclusion, the present study suggests more beneficial action of the combination therapy with ARB plus ACEI/amlodipine than the ARB monotherapy in nondiabetic renal disease. Since the reduction in BP was achieved to the same level, the distinct proteinuria-sparing action of these therapies is attributed to BP-independent mechanisms, which should vary depending on the agents used.",
keywords = "ACE inhibitors, Amlodipine, Candesartan, Proteinuria, Renal disease",
author = "Koichiro Honma and K. Hayashi and Takeshi Kanda and K. Yoshioka and I. Takamatsu and S. Tatematsu and H. Kumagai and Shu Wakino and T. Saruta",
year = "2004",
month = "12",
doi = "10.1038/sj.jhh.1001761",
language = "English",
volume = "18",
pages = "879--884",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease

AU - Honma, Koichiro

AU - Hayashi, K.

AU - Kanda, Takeshi

AU - Yoshioka, K.

AU - Takamatsu, I.

AU - Tatematsu, S.

AU - Kumagai, H.

AU - Wakino, Shu

AU - Saruta, T.

PY - 2004/12

Y1 - 2004/12

N2 - Although multiple antihypertensive agents are required to control blood pressure (BP) in chronic renal disease, it remains undetermined whether the combination therapy with angiotensin receptor blockers (ARB) plus calcium antagonists or angiotensin-converting enzyme inhibitors (ACEI) confers more preferable action on renal disease than the ARB monotherapy. In the present study, we compared the effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug treatment, the candesartan monotherapy (n=19) reduced BP from 154±3/93±2 to 146±3/88±2 mmHg (P< 0.05), and a similar magnitude of BP reductions was observed with the combination therapy with candesartan plus ACEI/amlodipine (from 153±2/95±2 to 144±2/88±2 mmHg, P<0.05, n=39). The depressor action of these therapies was sustained throughout the 12-month treatment. In contrast, the reduction in proteinuria was greater with the combination therapy (-52±3% at 12 months, n=39) than with the candesartan monotherapy (-25±3%, n=19), although the baseline values of proteinuria were nearly the same in the candesartan monotherapy group (1.74±0.22 g/day) and the combination therapy group (2.10±0.19 g/day, P>0.2). Of note, the proteinuria-sparing effect did not differ between the candesartan + ACEI group and the candesartan + amlodipine group. In conclusion, the present study suggests more beneficial action of the combination therapy with ARB plus ACEI/amlodipine than the ARB monotherapy in nondiabetic renal disease. Since the reduction in BP was achieved to the same level, the distinct proteinuria-sparing action of these therapies is attributed to BP-independent mechanisms, which should vary depending on the agents used.

AB - Although multiple antihypertensive agents are required to control blood pressure (BP) in chronic renal disease, it remains undetermined whether the combination therapy with angiotensin receptor blockers (ARB) plus calcium antagonists or angiotensin-converting enzyme inhibitors (ACEI) confers more preferable action on renal disease than the ARB monotherapy. In the present study, we compared the effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug treatment, the candesartan monotherapy (n=19) reduced BP from 154±3/93±2 to 146±3/88±2 mmHg (P< 0.05), and a similar magnitude of BP reductions was observed with the combination therapy with candesartan plus ACEI/amlodipine (from 153±2/95±2 to 144±2/88±2 mmHg, P<0.05, n=39). The depressor action of these therapies was sustained throughout the 12-month treatment. In contrast, the reduction in proteinuria was greater with the combination therapy (-52±3% at 12 months, n=39) than with the candesartan monotherapy (-25±3%, n=19), although the baseline values of proteinuria were nearly the same in the candesartan monotherapy group (1.74±0.22 g/day) and the combination therapy group (2.10±0.19 g/day, P>0.2). Of note, the proteinuria-sparing effect did not differ between the candesartan + ACEI group and the candesartan + amlodipine group. In conclusion, the present study suggests more beneficial action of the combination therapy with ARB plus ACEI/amlodipine than the ARB monotherapy in nondiabetic renal disease. Since the reduction in BP was achieved to the same level, the distinct proteinuria-sparing action of these therapies is attributed to BP-independent mechanisms, which should vary depending on the agents used.

KW - ACE inhibitors

KW - Amlodipine

KW - Candesartan

KW - Proteinuria

KW - Renal disease

UR - http://www.scopus.com/inward/record.url?scp=10044245874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044245874&partnerID=8YFLogxK

U2 - 10.1038/sj.jhh.1001761

DO - 10.1038/sj.jhh.1001761

M3 - Article

C2 - 15295613

AN - SCOPUS:10044245874

VL - 18

SP - 879

EP - 884

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 12

ER -